* . *
  • About
  • Advertise
  • Privacy & Policy
  • Contact
Saturday, September 6, 2025
Earth-News
  • Home
  • Business
  • Entertainment
    Pendulum Announce Homecoming 2026 Australian Tour – yahoo.com

    Pendulum Announces Thrilling Homecoming Tour Across Australia in 2026

    ITV Studios Launches New Entertainment Label – Global Bulletin – IMDb

    ITV Studios Unveils Exciting New Entertainment Label

    TS Entertainment bringing Malibu Jack’s to former Owensboro mall – Lane Report

    TS Entertainment Launches Malibu Jack’s at Former Owensboro Mall Location

    Jenny Han Dropped a Major ‘The Summer I Turned Pretty’ Easter Egg Revealing [SPOILER] – yahoo.com

    Jenny Han Just Unveiled a Huge ‘The Summer I Turned Pretty’ Easter Egg That Changes Everything [SPOILER]

    Liam Payne’s Cousin Ross Harris Honors Late Singer With Emotional Song ‘Bones’ – yahoo.com

    Liam Payne’s Cousin Ross Harris Honors Late Singer with Emotional New Song ‘Bones

    Country music star apologizes after drunken show ends with cops taking him down: ‘I’m not OK’ – PennLive.com

    Country Music Star Apologizes After Drunken Show Ends in Police Intervention: ‘I’m Not OK

  • General
  • Health
  • News

    Cracking the Code: Why China’s Economic Challenges Aren’t Shaking Markets, Unlike America’s” – Bloomberg

    Trump’s Narrow Window to Spread the Truth About Harris

    Trump’s Narrow Window to Spread the Truth About Harris

    Israel-Gaza war live updates: Hamas leader Ismail Haniyeh assassinated in Iran, group says

    Israel-Gaza war live updates: Hamas leader Ismail Haniyeh assassinated in Iran, group says

    PAP Boss to Niger Delta Youths, Stay Away from the Protest

    PAP Boss to Niger Delta Youths, Stay Away from the Protest

    Court Restricts Protests In Lagos To Freedom, Peace Park

    Court Restricts Protests In Lagos To Freedom, Peace Park

    Fans React to Jazz Jennings’ Inspiring Weight Loss Journey

    Fans React to Jazz Jennings’ Inspiring Weight Loss Journey

    Trending Tags

    • Trump Inauguration
    • United Stated
    • White House
    • Market Stories
    • Election Results
  • Science
  • Sports
  • Technology
    Coherent Joins LLNL’s STARFIRE Diode Technology Working Group to Advance Inertial Fusion Energy – GlobeNewswire

    Coherent Partners with LLNL’s STARFIRE Team to Drive Breakthroughs in Inertial Fusion Energy

    Gene Associated With Deadly Heart Disease in Golden Retrievers Identified – Technology Networks

    Breakthrough Discovery Uncovers Gene Behind Deadly Heart Disease in Golden Retrievers

    Monkey Island LNG Picks ConocoPhillips’ Liquefaction Technology – Hart Energy

    Monkey Island LNG Selects ConocoPhillips’ Advanced Liquefaction Technology for Next-Gen Energy Solutions

    Credo Technology Group Holding Ltd. (CRDO) Surpasses Q1 Earnings and Revenue Estimates – Yahoo Finance

    Credo Technology Group Surpasses Q1 Earnings and Revenue Expectations

    The Economist is hiring a science and technology correspondent – The Economist

    Exciting Opportunity: Become Our Next Science and Technology Correspondent!

    Blockchain lender Figure Technology seeks to raise up to $526M in IPO (FIGR:Pending) – Seeking Alpha

    Blockchain Lender Figure Technology Sets Sights on $526M in Thrilling IPO Launch

    Trending Tags

    • Nintendo Switch
    • CES 2017
    • Playstation 4 Pro
    • Mark Zuckerberg
No Result
View All Result
  • Home
  • Business
  • Entertainment
    Pendulum Announce Homecoming 2026 Australian Tour – yahoo.com

    Pendulum Announces Thrilling Homecoming Tour Across Australia in 2026

    ITV Studios Launches New Entertainment Label – Global Bulletin – IMDb

    ITV Studios Unveils Exciting New Entertainment Label

    TS Entertainment bringing Malibu Jack’s to former Owensboro mall – Lane Report

    TS Entertainment Launches Malibu Jack’s at Former Owensboro Mall Location

    Jenny Han Dropped a Major ‘The Summer I Turned Pretty’ Easter Egg Revealing [SPOILER] – yahoo.com

    Jenny Han Just Unveiled a Huge ‘The Summer I Turned Pretty’ Easter Egg That Changes Everything [SPOILER]

    Liam Payne’s Cousin Ross Harris Honors Late Singer With Emotional Song ‘Bones’ – yahoo.com

    Liam Payne’s Cousin Ross Harris Honors Late Singer with Emotional New Song ‘Bones

    Country music star apologizes after drunken show ends with cops taking him down: ‘I’m not OK’ – PennLive.com

    Country Music Star Apologizes After Drunken Show Ends in Police Intervention: ‘I’m Not OK

  • General
  • Health
  • News

    Cracking the Code: Why China’s Economic Challenges Aren’t Shaking Markets, Unlike America’s” – Bloomberg

    Trump’s Narrow Window to Spread the Truth About Harris

    Trump’s Narrow Window to Spread the Truth About Harris

    Israel-Gaza war live updates: Hamas leader Ismail Haniyeh assassinated in Iran, group says

    Israel-Gaza war live updates: Hamas leader Ismail Haniyeh assassinated in Iran, group says

    PAP Boss to Niger Delta Youths, Stay Away from the Protest

    PAP Boss to Niger Delta Youths, Stay Away from the Protest

    Court Restricts Protests In Lagos To Freedom, Peace Park

    Court Restricts Protests In Lagos To Freedom, Peace Park

    Fans React to Jazz Jennings’ Inspiring Weight Loss Journey

    Fans React to Jazz Jennings’ Inspiring Weight Loss Journey

    Trending Tags

    • Trump Inauguration
    • United Stated
    • White House
    • Market Stories
    • Election Results
  • Science
  • Sports
  • Technology
    Coherent Joins LLNL’s STARFIRE Diode Technology Working Group to Advance Inertial Fusion Energy – GlobeNewswire

    Coherent Partners with LLNL’s STARFIRE Team to Drive Breakthroughs in Inertial Fusion Energy

    Gene Associated With Deadly Heart Disease in Golden Retrievers Identified – Technology Networks

    Breakthrough Discovery Uncovers Gene Behind Deadly Heart Disease in Golden Retrievers

    Monkey Island LNG Picks ConocoPhillips’ Liquefaction Technology – Hart Energy

    Monkey Island LNG Selects ConocoPhillips’ Advanced Liquefaction Technology for Next-Gen Energy Solutions

    Credo Technology Group Holding Ltd. (CRDO) Surpasses Q1 Earnings and Revenue Estimates – Yahoo Finance

    Credo Technology Group Surpasses Q1 Earnings and Revenue Expectations

    The Economist is hiring a science and technology correspondent – The Economist

    Exciting Opportunity: Become Our Next Science and Technology Correspondent!

    Blockchain lender Figure Technology seeks to raise up to $526M in IPO (FIGR:Pending) – Seeking Alpha

    Blockchain Lender Figure Technology Sets Sights on $526M in Thrilling IPO Launch

    Trending Tags

    • Nintendo Switch
    • CES 2017
    • Playstation 4 Pro
    • Mark Zuckerberg
No Result
View All Result
Earth-News
No Result
View All Result
Home Health

High Confidence AD Drug Donanemab Will Get FDA Panel Nod

June 5, 2024
in Health
High Confidence AD Drug Donanemab Will Get FDA Panel Nod
Share on FacebookShare on Twitter

The Peripheral and Central Nervous System Drugs Advisory Committee of the US Food and Drug Administration (FDA) will meet on June 10 to discuss the biologics license application for donanemab for treatment of patients with early symptomatic Alzheimer’s disease (AD). 

The FDA delayed its decision on whether to approve the antiamyloid agent back in March, opting instead to hold a meeting of its outside experts to weigh the results of the phase 3 TRAILBLAZER-ALZ 2 trial. 

What is the evidence on donanemab? Why the FDA delay its decision, and what potential concerns might be raised by the advisory committee?

What Did TRAILBLAZER-ALZ 2 Find? 

Donanemab (Eli Lilly) is an investigational immunoglobulin G1 monoclonal antibody directed against an insoluble, modified, N-terminal, truncated form of beta-amyloid.

TRAILBLAZER-ALZ 2 evaluated the safety and efficacy of donanemab (vs placebo) in 1736 patients (mean age, 73 years) with early symptomatic AD (mild cognitive impairment or mild dementia) with evidence of amyloid and tau pathology on PET.

Donanemab was administered at a dose of 700 mg for the first three doses and 1400 mg thereafter. The drug was given once monthly for up to 72 weeks. Participants were stratified based on tau levels, a biomarker for AD progression, into a low/medium tau group and a combined tau group (low/medium and high tau).

As previously reported by Medscape Medical News, donanemab significantly reduced brain amyloid plaque burden and significantly slowed cognitive and functional decline, compared with placebo. 

The primary endpoint was change from baseline to 76 weeks on the integrated Alzheimer’s Disease Rating Scale (iADRS), which measures cognition and activities of daily living. 

The least-squares mean change in the iADRS score (range, 0-144; lower score indicates greater impairment) at 76 weeks was -6.02 in the donanemab group and -9.27 in the placebo group for the low/medium tau population and -10.19 in the donanemab group and -13.11 in the placebo group in the combined study population. Both results were statistically significant (P <.001>

Amyloid-related imaging abnormalities of edema or effusion occurred in 205 participants (24%; 52 symptomatic) in the donanemab group and 18 (2%; 0 symptomatic) in the placebo group. Infusion-related reactions occurred in 74 participants (8.7%) receiving donanemab and four participants (0.5%) receiving placebo. 

Three deaths in the donanemab group and one in the placebo group were considered treatment-related.

These results are “very exciting” and represent “the strongest data to date” for anti-amyloid monoclonal antibodies in AD,” Percy Griffin, PhD, director of scientific engagement, Alzheimer’s Association, told Medscape Medical News when the TRAILBLAZER-ALZ 2 results were released in July 2023.

Why the FDA Delay?

The FDA was expected to decide on donanemab in the first quarter of 2024, without a formal advisory committee meeting. 

The subsequent decision by the agency to convene a meeting of outside experts was “unexpected,” Anne White, executive vice president of Eli Lilly and Company and president of Lilly Neuroscience, said in a statement at the time. 

J.K. Wall, senior director of neuroscience communications at Lilly, told Medscape Medical News that the FDA informed the company that it wants to “further understand topics related to evaluating the safety and efficacy of donanemab, including the safety results in donanemab-treated patients.”

“It also wants to discuss the efficacy implications of the unique trial design of the TRAILBLAZER-ALZ 2 study, including its limited-duration dosing regimen that allowed patients to complete treatment based on an assessment of amyloid plaque and the inclusion of participants based on tau levels,” said Wall.

Howard Fillit, MD, co-founder and chief science officer of the Alzheimer’s Drug Discovery Foundation, told Medscape Medical News the FDA decision to convene an advisory meeting on donanemab is “not a setback, but another step forward in the drug approval process, with the regulatory agency doing its due diligence before the distribution of the drug to patients.”

What Are the Potential Concerns?

Fillit doesn’t necessarily believe the FDA panel will have any major or unexpected concerns about donanemab but will want to discuss differences in the design of the TRAILBLAZER-ALZ 2 study of donanemab compared with the CLARITY-AD study of lecanemab (Leqembi; Eisai Inc).

“I think donanemab and lecanemab are about the same in terms of efficacy and safety. The difference was in the way the trials were conducted in terms of the dosing schedule, the stopping rules, and the use of tau imaging. Those are the three things the FDA wanted to discuss with their advisors,” said Fillit. 

“I think everyone in the field feels this [advisory committee] meeting is mostly informational, and I would hope that donanemab would be approved by the FDA in the not-too-distant future,” Fillit added.

Wall told Medscape Medical News that Eli Lilly has “full confidence in donanemab’s meaningful results, and we look forward to discussing them further with the FDA, medical experts, patients, and care partners at the advisory committee hearing.”

Wall said it is “premature” to talk about price or discuss label requirements for donanemab once approved. 

However, if it is approved, the drug will be the third antiamyloid monoclonal antibody okayed in the US, behind aducanumab and lecanemab. Aducanumab is no longer available, after Biogen announced earlier this year that it would discontinue a postapproval study and commercialization of the controversial drug.

Fillit is looking forward to having two available antiamyloid agents. “Competition in the field is always good. It gives more validity to the mechanism of action to this new class of drugs and when you have two in class, I think that’s a good thing,” he said.

>>> Read full article>>>
Copyright for syndicated content belongs to the linked Source : Medscape – https://www.medscape.com/viewarticle/high-confidence-alzheimers-drug-donanemab-will-get-fda-panel-2024a1000ahq

Tags: confidenceDonanemabhealth
Previous Post

The Push to Get More People Into Long COVID Studies

Next Post

Stiff Arteries Raise Glaucoma Risk?

What the science says about acetaminophen, pregnant mothers and autism – NBC News

What the science says about acetaminophen, pregnant mothers and autism – NBC News

September 6, 2025
RFK Jr accused of ‘reckless disregard for science and the truth’ in Senate hearing – The Guardian

RFK Jr. Faces Fierce Backlash for ‘Reckless Disregard for Science and Truth’ in Heated Senate Hearing

September 6, 2025
Start The Go-Go Years Today: Ignite Your Early Retirement Lifestyle – Forbes

Start The Go-Go Years Today: Ignite Your Early Retirement Lifestyle – Forbes

September 6, 2025
When Sports Teach More Than Skills – American Enterprise Institute

When Sports Teach More Than Skills – American Enterprise Institute

September 6, 2025
Abby Dow and England near record territory as Australia search for upset – The Guardian

Abby Dow and England Close in on Record as Australia Hunts for an Upset

September 6, 2025
America is getting the economy we voted for – Noah Smith | Substack

America Is Finally Experiencing the Economy We Created

September 6, 2025
Pendulum Announce Homecoming 2026 Australian Tour – yahoo.com

Pendulum Announces Thrilling Homecoming Tour Across Australia in 2026

September 6, 2025
HHS responds to report about autism and acetaminophen : Shots – Health News – NPR

HHS Addresses New Findings on Autism and Acetaminophen Use

September 6, 2025
September 2, 2025: Trump administration news – CNN

September 2, 2025: Trump administration news – CNN

September 6, 2025
Blending art, culture and native plants at Wakamatsu – Mountain Democrat

Discover the Harmony of Art, Culture, and Native Plants at Wakamatsu

September 6, 2025

Categories

Archives

September 2025
MTWTFSS
1234567
891011121314
15161718192021
22232425262728
2930 
« Aug    
Earth-News.info

The Earth News is an independent English-language daily published Website from all around the World News

Browse by Category

  • Business (20,132)
  • Ecology (809)
  • Economy (828)
  • Entertainment (21,705)
  • General (16,888)
  • Health (9,869)
  • Lifestyle (841)
  • News (22,149)
  • People (830)
  • Politics (835)
  • Science (16,039)
  • Sports (21,327)
  • Technology (15,808)
  • World (809)

Recent News

What the science says about acetaminophen, pregnant mothers and autism – NBC News

What the science says about acetaminophen, pregnant mothers and autism – NBC News

September 6, 2025
RFK Jr accused of ‘reckless disregard for science and the truth’ in Senate hearing – The Guardian

RFK Jr. Faces Fierce Backlash for ‘Reckless Disregard for Science and Truth’ in Heated Senate Hearing

September 6, 2025
  • About
  • Advertise
  • Privacy & Policy
  • Contact

© 2023 earth-news.info

No Result
View All Result

© 2023 earth-news.info

No Result
View All Result

© 2023 earth-news.info

Go to mobile version